Literature DB >> 7541947

VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells.

K Maruno1, A Absood, S I Said.   

Abstract

Airway smooth muscle (ASM) cell proliferation contributes to increased airway resistance in bronchial asthma. We have examined the modulation of ASM proliferation by vasoactive intestinal peptide (VIP), a cotransmitter of airway relaxation. Human ASM cells were grown in culture as a monolayer. VIP (1.0 nM-1.0 microM) inhibited proliferation in a dose-dependent manner by up to 82% on day 2, but the related peptide glucagon had no effect. Histamine (100 nM-100 microM) increased cell counts by 66%, but in the presence of VIP, cell counts and [3H]thymidine incorporation were reduced by up to 55%. Adenosine 3',5'-cyclic monophosphate (cAMP)-promoting agents, including 3-isobutyl-1-methylxanthine, forskolin, and 8-bromo-adenosine 3',5'-cyclic monophosphate, alone and especially combined with VIP, reduced cell counts and [3H]thymidine incorporation, in correlation with cAMP levels. KT-5720 (1.0 nM-1.0 microM), a selective inhibitor of cAMP-dependent protein kinase A (PKA), abolished the inhibitory effect of VIP. The results show that VIP selectively and potently inhibits human ASM cell growth and multiplication, and nullifies the mitogenic effect of histamine, by a PKA-mediated mechanism. A deficiency of VIP may lead to ASM hyperplasia due to unopposed stimulation by endogenous mitogens.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541947     DOI: 10.1152/ajplung.1995.268.6.L1047

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  30 in total

Review 1.  Regulation of heterotrimeric G protein signaling in airway smooth muscle.

Authors:  Raymond B Penn; Jeffrey L Benovic
Journal:  Proc Am Thorac Soc       Date:  2008-01-01

Review 2.  Embracing emerging paradigms of G protein-coupled receptor agonism and signaling to address airway smooth muscle pathobiology in asthma.

Authors:  Raymond B Penn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-02-16       Impact factor: 3.000

Review 3.  Motility, survival, and proliferation.

Authors:  William T Gerthoffer; Dedmer Schaafsma; Pawan Sharma; Saeid Ghavami; Andrew J Halayko
Journal:  Compr Physiol       Date:  2012-01       Impact factor: 9.090

4.  Bladder dysfunction and altered somatic sensitivity in PACAP-/- mice.

Authors:  Victor May; Margaret A Vizzard
Journal:  J Urol       Date:  2010-02       Impact factor: 7.450

5.  Lentiviral gene therapy vectors encoding VIP suppressed diabetes-related inflammation and augmented pancreatic beta-cell proliferation.

Authors:  Fulya Erendor; Elif Ozgecan Sahin; Ahter D Sanlioglu; Mustafa Kemal Balci; Thomas S Griffith; Salih Sanlioglu
Journal:  Gene Ther       Date:  2020-07-30       Impact factor: 5.250

6.  Treating pulmonary arterial hypertension: current treatments and future prospects.

Authors:  Shahzad G Raja; Shahbaz M Raja
Journal:  Ther Adv Chronic Dis       Date:  2011-11       Impact factor: 5.091

7.  Different proliferative responses of Gi/o-protein-coupled receptors in human myometrial smooth muscle cells. A possible role of calcium.

Authors:  U K Nilsson; M Grenegård; G Berg; S P Svensson
Journal:  J Mol Neurosci       Date:  1998-08       Impact factor: 3.444

8.  Urinary bladder function and somatic sensitivity in vasoactive intestinal polypeptide (VIP)-/- mice.

Authors:  Simon Studeny; Bopaiah P Cheppudira; Susan Meyers; Elena M Balestreire; Gerard Apodaca; Lori A Birder; Karen M Braas; James A Waschek; Victor May; Margaret A Vizzard
Journal:  J Mol Neurosci       Date:  2008-06-17       Impact factor: 3.444

Review 9.  Pathogenic mechanisms of pulmonary arterial hypertension.

Authors:  Stephen Y Chan; Joseph Loscalzo
Journal:  J Mol Cell Cardiol       Date:  2007-09-20       Impact factor: 5.000

10.  Expression of phosphorylated cAMP response element binding protein (p-CREB) in bladder afferent pathways in VIP-/- mice with cyclophosphamide (CYP)-induced cystitis.

Authors:  Dorthe G Jensen; Simon Studeny; Victor May; James Waschek; Margaret A Vizzard
Journal:  J Mol Neurosci       Date:  2008-02-26       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.